Processa Pharma Q3 2024 GAAP EPS $(1.03) Misses $(1.00) Estimate
Portfolio Pulse from Benzinga Newsdesk
Processa Pharma reported a Q3 2024 GAAP EPS of $(1.03), missing the analyst consensus estimate of $(1.00) by 3%.
October 30, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Processa Pharma's Q3 2024 earnings per share of $(1.03) missed the analyst estimate of $(1.00) by 3%, indicating a larger than expected loss.
The reported EPS of $(1.03) is worse than the expected $(1.00), suggesting the company is underperforming relative to analyst expectations. This could lead to negative sentiment and short-term pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100